Who is sponsoring NCT04782765?

NCT04782765 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT04782765?

Interventions in NCT04782765: Camrelizumab+Chemotherapy+Chemoradiotherapy.

What condition does NCT04782765 study?

NCT04782765 studies Disease-free Survival Rate.

Is NCT04782765 still recruiting?

NCT04782765 is currently status unknown. Last updated 4 March 2021.

Last reviewed 2021-03-04 · How we verify

NCT04782765

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma

Status unknown Phase 2 Last updated 4 March 2021

What this trial tests

Phase 2 trial testing Camrelizumab+Chemotherapy+Chemoradiotherapy in Disease-free Survival Rate in 59 participants. Status unknown.

Timeline

20 March 2021

Primary endpoint
20 March 2023

20 March 2025

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	59
Start date	20 March 2021
Primary completion	20 March 2023
Estimated completion	20 March 2025
Sites	1 location across China

Drugs / interventions tested

Camrelizumab+Chemotherapy+Chemoradiotherapy — full drug profile →

Conditions studied

Disease-free Survival Rate — all drugs for Disease-free Survival Rate →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Under 70, any sex, with Disease-free Survival Rate. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To see the effect if a combination of neoadjuvant chemotherapy combined with Camrelizumab followed by chemoradiotherapy in treating patients without distant metastasis nasopharyngeal carcinoma

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Nasopharyngeal carcinoma: current views on the tumor microenvironment's impact on drug resistance and clinical outcomes.
Liu H, Tang L, Li Y, Xie W, et al · · 2024 · cited 85× · PMID 38254110 · DOI 10.1186/s12943-023-01928-2
Current status and advances of immunotherapy in nasopharyngeal carcinoma.
Xu JY, Wei XL, Wang YQ, Wang FH. · · 2022 · cited 62× · PMID 35547095 · DOI 10.1177/17588359221096214
Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.
Siak PY, Heng WS, Teoh SSH, Lwin YY, et al · · 2023 · cited 33× · PMID 37932756 · DOI 10.1186/s12967-023-04673-8
Advance in integrating platinum-based chemotherapy with radiotherapy for locally advanced nasopharyngeal carcinoma.
Zhu F, Wu Y, Wang H. · · 2023 · cited 9× · PMID 37860184 · DOI 10.3389/fonc.2023.1259331
Induction chemotherapy plus camrelizumab combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma in non-endemic areas: a phase 2 clinical trial in North China.
Wang Z, Sun Y, Wang Q, Chai Y, et al · · 2025 · cited 5× · PMID 40016735 · DOI 10.1186/s12916-025-03964-9
A Systematic Review and Meta-Analysis of Studies Comparing Concurrent Chemoradiotherapy With Radiotherapy Alone in the Treatment of Stage II Nasopharyngeal Carcinoma.
Xu YC, Chen KH, Liang ZG, Zhu XD. · · 2022 · cited 2× · PMID 35903695 · DOI 10.3389/fonc.2022.843675

Verify or expand the search:

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04782765 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 4 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04782765.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing